Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma

Yang, Chi-Ying; Lin, Ro-Ting; Chen, Chi-Yi; Yeh, Chun-Chieh; Tseng, Chao‐Ming; Lee, Teng‐Yu; Chu, Chia-Shen; Lin, Jaw–Town

doi:10.1016/j.jfma.2022.07.003

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA19-9, if elevated, is useful in following patients with known disease [37]. However, the sensitivity and specificity rate of serum CA19-9 alone in diagnosing PDAC have been reported to be low (i.e., about 78.2% and 82.8%, respectively) [38].…”

Section: Resultsmentioning

confidence: 99%

Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins

Caputo

Coppola

Quagliarini

et al. 2022

Cancers

View full text Add to dashboard Cite

The development of new tools for the early detection of pancreatic ductal adenocarcinoma (PDAC) represents an area of intense research. Recently, the concept has emerged that multiplexed detection of different signatures from a single biospecimen (e.g., saliva, blood, etc.) may exhibit better diagnostic capability than single biomarkers. In this work, we develop a multiplexed strategy for detecting PDAC by combining characterization of the nanoparticle (NP)-protein corona, i.e., the protein layer that surrounds NPs upon exposure to biological fluids and circulating levels of plasma proteins belonging to the acute phase protein (APPs) family. As a first step, we developed a nanoparticle-enabled blood (NEB) test that employed 600 nm graphene oxide (GO) nanosheets and human plasma (HP) (5% vol/vol) to produce 75 personalized protein coronas (25 from healthy subjects and 50 from PDAC patients). Isolation and characterization of protein corona patterns by 1-dimensional (1D) SDS-PAGE identified significant differences in the abundance of low-molecular-weight corona proteins (20–30 kDa) between healthy subjects and PDAC patients. Coupling the outcomes of the NEB test with the circulating levels of alpha 2 globulins, we detected PDAC with a global capacity of 83.3%. Notably, a version of the multiplexed detection strategy run on sex-disaggregated data provided substantially better classification accuracy for men (93.1% vs. 77.8%). Nanoliquid chromatography tandem mass spectrometry (nano-LC MS/MS) experiments allowed to correlate PDAC with an altered enrichment of Apolipoprotein A-I, Apolipoprotein D, Complement factor D, Alpha-1-antichymotrypsin and Alpha-1-antitrypsin in the personalized protein corona. Moreover, other significant changes in the protein corona of PDAC patients were found. Overall, the developed multiplexed strategy is a valid tool for PDAC detection and paves the way for the identification of new potential PDAC biomarkers.

show abstract

Section: Resultsmentioning

confidence: 99%

Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins

Caputo

Coppola

Quagliarini

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Remarkably, the sensitivity reached 100% when utilizing more than three markers. These results initiated the thought that simultaneous assessment of markers while screening on a vast scale may help boost detection rates of pancreatic cancer [ 19 ]. Based on this study, Yang et al conducted simultaneous measurements of more commonly used biomarkers like serum CA 19-9, pancreatic elastase-1, pancreatic lipase, and pancreatic amylase.…”

Section: Reviewmentioning

confidence: 99%

“…The objective was to assess the precision of individual markers and combinations of two, three, or four markers for early detection of PDAC. Surprisingly, including lipase, amylase, or elastase-1 in the diagnostic process did not yield enhanced diagnostic accuracy, and the detection rate fell to 17.1% when all four abnormal markers were used [ 19 ].…”

Section: Reviewmentioning

confidence: 99%

Holistic Understanding of the Role of Carbohydrate Antigen 19-9 in Pancreatic Cancer Screening, Early Diagnosis, and Prognosis: A Systematic Review

Janga,

Sambe,

Yasir

et al. 2023

Cureus

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a significant challenge due to its silent progression and well-advanced, unresectable, complicated presentation. Detecting this disease early on is crucial, and researchers have been investigating various potential biological markers, such as carbohydrate antigen 19-9 (CA 19-9), hoping to find indicators that can aid in its early detection. The primary focus of this review is on the diagnostic usefulness of CA 19-9 in detecting pancreatic cancer (PC) in the beginning stage and its usefulness in predicting progression. The database search of articles from PubMed, PMC, the Cochrane Library, and Google Scholar identified 227 articles published from 2013 to 2023. The keyword mix used in the search technique included terms like "CA 19-9," "pancreatic cancer," "diagnosis," and "early detection." This study provides evidence of CA 19-9's ability in detecting PDAC in the pre-diagnostic stage. But since the outcomes were inconsistent among the included trials, further analysis is required to develop standardized diagnostic criteria and methodologies. Furthermore, because of the variability of the study, it is not easy to make firm conclusions on CA 19-9's sensitivity as well as specificity in the first stage of pancreatic neoplasm. This in-depth overview of the available literature provides new insights into using CA 19-9 as a biological marker for detecting undiagnosed PC before progressing into the advanced stage, and was proven beneficial. However, this has to be shown in broader research with adequate sample size. Although it shows promise as a diagnostic tool, further study is required to confirm these findings.

show abstract

“…Novel serum biomarkers that have been recently identified largely fall into one of the following categories: cell-free DNA, cell-free RNA, cell-free proteins, circulating tumor cells, and exosomes. Markers that increase the diagnostic utility of CA19-9 include endostatin and collagen IV [ 44 ], circulating tumor-associated autoantibodies [ 45 ], methylated HOXA1 and SST [ 46 ], and pancreatic elastase-1, amylase, and lipase [ 47 ]. Moreover, new markers such as mitochondrially derived DNA and lipids in exosomes have been found in patients with PDAC [ 48 ].…”

Section: Improvements To Current Diagnostic Approachesmentioning

confidence: 99%

Advances in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma and Premalignant Pancreatic Lesions

et al. 2023

View full text Add to dashboard Cite

Pancreatic cancer is one of the most lethal human malignancies, in part because it is often diagnosed at late stages when surgery and systemic therapies are either unfeasible or ineffective. Therefore, diagnosing pancreatic cancer in earlier stages is important for effective treatment. However, because the signs and symptoms may be nonspecific and not apparent until the disease is at a late stage, the timely diagnoses of pancreatic cancer can be difficult to achieve. Recent studies have shown that selective screening and increased usage of biomarkers could improve the early diagnosis of pancreatic cancer. In this review, we discuss recent advancements in the early detection of pancreatic ductal carcinoma and precancerous lesions. These include innovations in imaging modalities, the diagnostic utility of various biomarkers, biopsy techniques, and population-based surveillance approaches. Additionally, we discuss how machine learning methods are being applied to develop integrated methods of identifying individuals at high risk of developing pancreatic disease. In the future, the overall survival of pancreatic cancer patients could be improved by the development and adoption of these new methods and techniques.

show abstract

Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma

Cited by 4 publications

References 28 publications

Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins

Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins

Holistic Understanding of the Role of Carbohydrate Antigen 19-9 in Pancreatic Cancer Screening, Early Diagnosis, and Prognosis: A Systematic Review

Advances in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma and Premalignant Pancreatic Lesions

Contact Info

Product

Resources

About